Immuron Granted US Patent for NASH Treatment
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: GlobeNewswire
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today pleased to announced that a Notice of Allowance has been received from the United States Patent and Trademarks Office (USPTO) for Immuron’s new patent application (U.S Application No. 13/817,414), entitled “Anti-LPS Enriched Immunoglobulin for Use in treatment and/or Prophylaxis of a Pathological Disorder.” The patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis (NASH) with a colostrum-based composition, as developed by Immuron. The market for NASH treatment has come under increased focus, as companies including Bristol-Myers Squibb and Pfizer have referenced efforts to bolster their product development in the sector. According to Reuters,
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Immuron Presentation Australian Biologics Festival 2024GlobeNewswire
- Immuron achieves record Travelan® sales [Yahoo! Finance]Yahoo! Finance
- Immuron achieves record Travelan® salesGlobeNewswire
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation [Yahoo! Finance]Yahoo! Finance
IMRN
Sec Filings
- 3/14/24 - Form 6-K
- 3/5/24 - Form 6-K
- 2/28/24 - Form 6-K
- IMRN's page on the SEC website